Drug · CHEMBL121
ROSIGLITAZONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ROSIGLITAZONE. Drugs and targets, record CHEMBL121. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL121
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Avandamet, Avandaryl, BRL-49653, Gaudil, NSC-758698, Rezult, Rosiglitazona, Rosiglizole, Rosvel, TDZ-01
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor gamma agonist | AGONIST | https://conductscience.org/library/genes/5468 |
Source ChEMBL
Diseases59
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| type 2 diabetes mellitus | Approval | TTD | 66 | 59 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
| Insulin resistance | Phase 3 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=HP_0000855 |
| Alzheimer disease | Phase 3 | ClinicalTrials.gov and TTD | 11 | 10 | https://conductscience.org/library/drugs?q=MONDO_0004975 |
| atherosclerosis | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005311 |
| diabetes mellitus | Approval | ATC | 4 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005015 |
| abnormal glucose tolerance | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=EFO_0002546 |
| chronic kidney disease | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005300 |
| inherited lipid metabolism disorder | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0002525 |
| metabolic dysfunction-associated steatohepatitis | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0007027 |
| Impaired glucose tolerance | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0040270 |
1 to 10 of 59Source Open Targets
See all 59 diseasesTrials183
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 9 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00379769 | RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes | Phase 3 | 4,447 | 2009-11-13 | rosiglitazone | Its name | ClinicalTrials.gov |
| NCT00006305 | Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes | Phase 3 | 2,368 | 2011-05-12 | thiazolidinediones | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00032487 | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Phase 3 | 1,791 | 2014-02-12 | rosiglitazone | Its name | ClinicalTrials.gov |
| NCT00348309 | Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease | 1,496 | 2017-11-28 | rosiglitazone | Its name | ClinicalTrials.gov | |
| NCT00348140 | Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease | Phase 3 | 1,468 | 2017-09-05 | rosiglitazone | Its name | ClinicalTrials.gov |
| NCT00490568 | Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers | Phase 3 | 1,461 | 2017-11-13 | rosiglitazone | Its name | ClinicalTrials.gov |
| NCT00879970 | Thiazolidinedione Intervention With Vitamin D Evaluation | Phase 4 | 1,332 | 2011-12-13 | rosiglitazone | Its name | ClinicalTrials.gov |
| NCT00428090 | Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease | Phase 3 | 862 | 2017-05-19 | rosiglitazone | Its name | ClinicalTrials.gov |
| NCT00081328 | Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) | Phase 3 | 699 | 2014-12-16 | rosiglitazone | Its name | ClinicalTrials.gov |
| NCT00386100 | A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin | Phase 4 | 688 | 2011-04-05 | rosiglitazone | Its name | ClinicalTrials.gov |
1 to 10 of 183
See all 183 trialsComparisons in its trials37
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions | 88 of 2,220 | 96 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 50 of 2,220 | 63 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions | 88 of 2,220 | 96 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 68 of 2,220 | 60 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions | 186 of 2,220 | 191 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG vs Combined MET/SU: Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions | 181 of 2,220 | 188 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events | 321 of 2,220 | 323 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions | 72 of 2,220 | 62 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause | 139 of 2,220 | 160 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG: Main Study and Observational Follow-up vs Combined MET/SU: Main Study and Observational Follow-up: Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined | 0 of 2,220 | 0 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
1 to 10 of 37
See all 37 comparisons in its trialsPapers from its trials216
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials13
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Paired Associate Learning | 2 | 0 | ConductCognition |
| Stroop Color-Word Test | 2 | 1 | ConductCognition |
| Verbal Fluency | 2 | 0 | ConductCognition |
| Arithmetic Fluency Task | 1 | 0 | ConductCognition |
| Clock Drawing Task | 1 | 0 | ConductCognition |
| Choice Reaction Time | 1 | 0 | ConductCognition |
| Delayed Recall Module | 1 | 0 | ConductCognition |
| Object Location Memory Task | 1 | 0 | ConductCognition |
| Picture Naming Test | 1 | 0 | ConductCognition |
| Short Story Recall | 1 | 0 | ConductCognition |
1 to 10 of 13
See all 13 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL121
GET https://conductscience.org/api/drugs/v1/CHEMBL121/diseases?page=2